DBVTechnologies

DBV Technologies is a clinical-stage specialty biopharmaceutical company focused on immunotherapy. Co.'s therapeutic approach is based on epicutaneous immunotherapy (EPIT), its proprietary method of delivering biologically active compounds to immune systems through intact skin using a platform called Viaskin. Viaskin is an electrostatic patch that offers a self-administered, non-invasive immunotherapy to patients. Once applied on intact skin, Viaskin forms a condensation chamber that hydrates the skin and solubilizes the antigen, allowing it to penetrate the epidermis, where it's captured by Langerhans cells. Co.'s patients include infants and children suffering from severe food allergies.
  • TickerDBV
  • ISINFR0010417345
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance

Analysts

Eric Le Berrigaud ...
  • Gary Waanders
  • Hugo Solvet
  • Jean-Jacques Le Fur
  • Ross Blair
  • Victor Floc’h

Top Picks for Q3 2019: Roche stays; DBV and Novartis jump in

Looking back at Q2 2019 What to expect for Q3 2019 Our selection for Q3 2019: one confirmation, two come-backs

DBV TECHNOLOGIES sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of DBV TECHNOLOGIES (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date June 18, 2019, the closing price was EUR 15.14 and its target price was estimated at EUR 5.94.

Eric Le Berrigaud ...
  • Gary Waanders
  • Hugo Solvet
  • Jean-Jacques Le Fur
  • Ross Blair
  • Victor Floc’h

Top Picks for Q3 2019: Roche stays; DBV and Novartis jump in

Looking back at Q2 2019 What to expect for Q3 2019 Our selection for Q3 2019: one confirmation, two come-backs

Hugo Solvet

DBV TECHNOLOGIES: The earlier the better (CoFAR trial poster presented at EAACI) | BUY | EUR46(+177%)

DBV TECHNOLOGIES - BUY | EUR46(+177%) The earlier the better (CoFAR trial poster presented at EAACI) Additional data from CoFAR6 pointing in the right direction Median age of successes supportive of use in toddlers Dense Q3 newsflow

Hugo Solvet

DBV TECHNOLOGIES: CoFAR6 (30-month) supportive of long-term treatment with Viaskin Peanuts | BUY | EUR46(+179%)

DBV TECHNOLOGIES - BUY | EUR46(+179%) CoFAR6 (30-month) supportive of long-term treatment with Viaskin Peanuts 3-times increase in successfully consumed dose Not surprising to see no patient passing the food challenge Confirmed safety profile

Hugo Solvet

DBV TECHNOLOGIES: 30-months data from CoFAR6 to provide additional relief to the shares | BUY | EUR46(+185%)

DBV TECHNOLOGIES - BUY | EUR46(+185%) 30-months data from CoFAR6 to provide additional relief to the shares Updated CoFAR6 trial to be presented at EAACI De-risking PEOPLE phase III readout in H2 2019 Upholding the commercial positioning

Hugo Solvet

DBV TECHNOLOGIES: Thoughts ahead of BLA resubmission awaited for Q3’19 | BUY | EUR46(+172%)

DBV TECHNOLOGIES - BUY | EUR46(+172%) Thoughts ahead of BLA resubmission awaited for Q3’19 Very low-risk for BLA resubmission to slip into Q4 There is only upside to the anticipated review timeline Deciphering the recent ICER review : no headwinds for DBV

1 director sold

A director at Dbv Technologies sold 30,000 shares at 33.090EUR and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names ...

Christophe-Raphaël Ganet ...
  • Jean Sassus
  • Martial Descoutures
  • Pierre Corby
  • Steven Gould

ODDO BHF Small & MIDCAP MORNING NEWS - 04/04/2019

...

Christophe-Raphaël Ganet ...
  • Jean Sassus
  • Martial Descoutures
  • Pierre Corby
  • Steven Gould

ODDO BHF Small & MIDCAP MORNING NEWS - 04/04/2019

...

Alfred Glaser ...
  • Delphine Brault
  • Jeremy Garnier
  • Jerôme Bodin
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 03/06/2019

...

Alfred Glaser ...
  • Delphine Brault
  • Jeremy Garnier
  • Jerôme Bodin
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri

ODDO BHF Small & MIDCAP MORNING NEWS - 06/03/2019

...

Ahmed Ben Salem ...
  • Alfred Glaser
  • Aurelien Sivignon
  • Delphine Brault
  • Emmanuel Matot
  • Florent Laroche-Joubert
  • Jean-François Granjon
  • Martial Descoutures
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 02/14/2019

...

DBV TECHNOLOGIES sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of DBV TECHNOLOGIES (FR), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date June 18, 2019, the closing price was EUR 15.14 and its target price was estimated at EUR 5.94.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

Florian Béchaz

DBV Technologies - Assemblée générale des actionnaires du 24 mai 2019

Proxinvest attire l'attention des actionnaires sur plusieurs points. Tout d'abord la société a connu un retrait volontaire de sa demande BLA (Biologics License Application) pour son produit Viaskin® Peanut. Ce retrait a entrainé une chute du cours de bourse de près de 60%. Par ailleurs la société a décidé : "n’octroyer aucune rémunération variable au titre de l’exercice 2018 pour les membres du Comité exécutif, en ce compris le Président du Conseil, le Directeur Général et les Directeurs Généraux Délégués, en raison du retrait du BLA." Par ailleurs les commissaires aux comptes dans leurs rap...

Jehanne Leroy

Proxy Report - 22/06/2018

La société propose un vote sur les politiques de rémunérations 2018 des dirigeants (résolutions 16 à 18). Cependant, elle ne présente pas les montants en jeu pour ledit exercice, rendant ainsi impossible toute estimation des montants totaux en jeu ou de la structure de rémunération mise en place par la société. De la même façon, la société propose d'approuver les rémunérations 2017 de ses dirigeants mais ne communique ni la nature des indicateurs utilisés dans le cadre du calcul du bonus annuel ni leurs taux de réalisation individuels, rendant impossible pour l'actionnaire de comprendre comme...

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

Matthieu DRIOL

Analyse court terme - DBV TECHNOLOGIES : Les prix baissent.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 31,00 €. La tendance baissière serait remise en cause au-dessus de 45,50 €.

Matthieu DRIOL

Short term view - DBV TECHNOLOGIES : Falling prices.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at €31.00. The bearish trend would be challenged above €45.50.

Matthieu DRIOL

Analyse court terme - DBV TECHNOLOGIES : La tendance est baissière.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 31,00 €. La tendance baissière serait remise en cause au-dessus de 45,50 €.

Matthieu DRIOL

Short term view - DBV TECHNOLOGIES : The trend is bearish.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at €31.00. The bearish trend would be challenged above €45.50.

Jérôme VINERIER

Analyse moyen terme - DBV TECHNOLOGIES : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Le mouvement se poursuit. Le prochain objectif est à 28,40 €, puis 21,60 €. Le franchissement de 47,40 € remettrait en cause la suite de la baisse.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch